A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
Active, not recruiting · Phase 2 · NCT06421636
Conditions: Non-Transfusion Dependent Beta-Thalassemia (NTDT)
At a glance
- Research payments reported, 2025
- $46,125
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 19
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN7999 (drug), Placebo (drug)
- Dates
- Started 2024-09-30; completion 2026-12-03
- Results posted
- Not yet
This study is researching an experimental drug called REGN7999 (called "study drug"). The study is focused on patients with non-transfusion dependent beta-thalassemia. The aim of the study is to see how safe and effective the study drug is. The study is looking at several other research questions, including: * Whether the study drug lowers extra iron levels in the body * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
From ClinicalTrials.gov, last updated 2026-07-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $46,125 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Weill Medical College of Cornell University $46,125
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.